Merck
CN
  • Overdose with levetiracetam: a case report and review of the literature.

Overdose with levetiracetam: a case report and review of the literature.

Journal of clinical pharmacy and therapeutics (2012-06-26)
T M Larkin, A N Cohen-Oram, G Catalano, M C Catalano
摘要

Levetiracetam is an anticonvulsant agent that was first approved for use in the United States in 1999 and has a maximum recommended adult dose of 3000 mg daily. It has been noted to have a relatively mild adverse effect profile, with the most common side effects being somnolence, asthenia, infection, and dizziness. Although it has been widely prescribed, there have been few reports on the safety of this agent in overdose. We present the case of a 49-year-old man who ingested over 22 500 mg of levetiracetam in a suicide attempt. The patient arrived at the Emergency Department 6·5 h after the ingestion and was noted to have no significant sequelae from the ingestion. Based on the patient's weight, he ingested 358 mg/kg of levetiracetam. The few cases of levetiracetam overdose reported in the literature were associated with relatively mild, if any, symptoms. However, one patient who overdosed on levetiracetam became obtunded and developed significant respiratory distress that required intubation and ventilatory support. Therefore, clinical vigilance is still required in the cases of levetiracetam overdose.

材料
货号
品牌
产品描述

Supelco
左乙拉西坦, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Levetiracetam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
USP
左乙拉西坦, United States Pharmacopeia (USP) Reference Standard
左乙拉西坦, European Pharmacopoeia (EP) Reference Standard